Mercer Global Advisors Inc. ADV Has $15.51 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Mercer Global Advisors Inc. ADV raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.5% in the 2nd quarter, Holdings Channel.com reports. The fund owned 30,753 shares of the medical research company’s stock after buying an additional 3,405 shares during the quarter. Mercer Global Advisors Inc. ADV’s holdings in Thermo Fisher Scientific were worth $15,514,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Thermo Fisher Scientific in the 1st quarter valued at $26,000. MV Capital Management Inc. raised its holdings in Thermo Fisher Scientific by 577.8% in the 2nd quarter. MV Capital Management Inc. now owns 61 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 52 shares in the last quarter. Roble Belko & Company Inc raised its holdings in Thermo Fisher Scientific by 914.3% in the 1st quarter. Roble Belko & Company Inc now owns 71 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 64 shares in the last quarter. Cranbrook Wealth Management LLC raised its holdings in Thermo Fisher Scientific by 58.7% in the 1st quarter. Cranbrook Wealth Management LLC now owns 73 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 27 shares in the last quarter. Finally, Bedel Financial Consulting Inc. raised its holdings in Thermo Fisher Scientific by 65.0% in the 2nd quarter. Bedel Financial Consulting Inc. now owns 66 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 26 shares in the last quarter. 85.50% of the stock is owned by hedge funds and other institutional investors.

Shares of Thermo Fisher Scientific stock opened at $562.40 on Wednesday. Thermo Fisher Scientific Inc. has a one year low of $412.80 and a one year high of $575.63. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.78 and a quick ratio of 2.11. The stock’s 50-day moving average is $542.01 and its 200 day moving average is $494.08. The firm has a market cap of $221.26 billion, a price-to-earnings ratio of 26.07, a PEG ratio of 1.33 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 28th. The medical research company reported $5.60 earnings per share for the quarter, topping analysts’ consensus estimates of $5.51 by $0.09. Thermo Fisher Scientific had a return on equity of 29.43% and a net margin of 22.47%. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 22.07 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, October 15th. Investors of record on Wednesday, September 15th will be paid a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a yield of 0.18%. The ex-dividend date of this dividend is Tuesday, September 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 5.32%.

TMO has been the subject of a number of research analyst reports. KeyCorp boosted their price target on Thermo Fisher Scientific from $520.00 to $555.00 and gave the stock an “overweight” rating in a report on Monday, July 12th. BTIG Research boosted their price target on Thermo Fisher Scientific from $590.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday, July 29th. SVB Leerink reissued an “outperform” rating on shares of Thermo Fisher Scientific in a report on Monday, July 19th. Cowen boosted their price objective on Thermo Fisher Scientific from $525.00 to $560.00 and gave the stock an “outperform” rating in a research report on Thursday, July 29th. Finally, Argus boosted their price objective on Thermo Fisher Scientific from $530.00 to $600.00 and gave the stock a “buy” rating in a research report on Wednesday, August 4th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $547.95.

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Wednesday, August 4th. The stock was sold at an average price of $539.05, for a total value of $5,390,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jim P. Manzi sold 572 shares of the stock in a transaction that occurred on Friday, July 30th. The stock was sold at an average price of $536.54, for a total value of $306,900.88. The disclosure for this sale can be found here. 0.44% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific, Inc engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Featured Article: Trade War

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.